ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

Carcinogenicity Test For Cis-Platinum Needed, DCT Says, But Declines To Pay For It

June 16, 1978

Greatest Need Of Cancer Care Givers: “Will to Work Together,” ACCC President Anderson Says

August 15, 1986

Seer Data On Cancer Incidence Among Minorities Published

May 10, 1996

Funding opportunities listed.

January 9, 2004

Komen, ACS Support Payment Off-Protocol; Dilemma for Advocates

April 16, 1999

HHS Hearings to Form National Breast Cancer Strategy. Shalala Says

October 29, 1993